Adefovir dipivoxil resistance patterns in patients with lamivudine-resistant chronic hepatitis B

Antiviral Therapy

Volumn 14, Issue 4, 2009, Pages 557-565

  Santantonio, Teresa ^a   Fasano, Massimo ^b   Durantel, Sandra ^c,d,e   Barraud, Luc ^c,d,e   Heichen, Manuela ^b   Guastadisegni, Angela ^b   Pastore, Giuseppe ^b   Zoulim, Fabien ^e,f,g  

^a UNIVERSITY OF FOGGIA   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c Eurofins Medinet Inc   (Germany)

^d BioAlliance Pharma   (France)

^e INSERM   (France)

^f UNIVERSITÉ LYON 1   (France)

^g HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; ADENINE; DRUG DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS DNA;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUTATION; PHENOTYPE; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT DURATION; ANTIVIRAL RESISTANCE; BLOOD; CELL LINE; DRUG COMBINATION; DRUG EFFECT; ENZYMOLOGY; GENETICS; HEPATITIS B VIRUS; MIDDLE AGED; RISK FACTOR;

ADENINE; ADULT; AGED; CELL LINE; DNA, VIRAL; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; RNA-DIRECTED DNA POLYMERASE;

EID: 68549122654     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovit dipivoxil for HBeAg negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131:1743-1751.
2. Peters MG, Hann HH, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126:91-101.
3. Perrillo R, Hann HW, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126:81-90.
4. Schiff E, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 2007; 13:349-360.
5. Lampertico P, Viganò M, Manenti E, Iavone M, Lunghi G, Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005; 42:1414-1419.
6. Zoulim F. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogues in chronic hepatitis B virus infection. Antiviral Res 2004; 64:1-15.
7. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007; 45:307-313.
8. Fung SK, Chae HB, Fontana RJ, et al. Virological response and resistance to adefovir in patients with cbonic hepatitis B. J Hepatol 2006; 44:283-290.
9. Yeon JE, Yoo W, Hong SP, et al. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut 2006; 55:1488-1495.
10. Lampertico P, Marzano A, Levrero M, et al. Adefovir and lamivudine combination therapy is superior to adefovir monotherapy for lamivudine-resistant patients with HBeAg-negative chronic hepatitis B. Hepatology 2006; 44 Suppl 1:693A.
11. Gaia S, Borbon V, Swedile A, et al. Lamivudine-resistant chronic hepatitis B: an observational study on adefovir in monotherapy or in association with lamivudine. J Hepatol 2008; 48:540-547.
12. Lee YS, Chung, Y-H, Ryu SH, et al. Hepatitis B virus with rtL80V/I mutation associates with poor response to adefovir dipivoxil therapy. Hepatology 2005; 42 Suppl 1:575A.
13. Locarnini S, Mason WS. Cellular and virological mechanisms of HBV drug resistance. J Hepatol 2006; 44:422-431.
14. Shaw T, Bartholomeusz A, Locarnini S. HBV drug resistance: mechanisms, detection and interpretation. J Hepatol 2006; 44:593-606.
15. Villet S, Pichoud C, Billioud G, et al. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol 2008; 48:747-755.
16. Lok AS, Zoulim F, Locarnini S, et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for managemenf. Hepatology 2007; 46:254-265.
17. Pawlotsky JM, Tusheiko G, Hatzakis A, et al. Virologic monitoring of hepatitis B therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology 2008; 134:405-415.
18. Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop. roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007; 5:890-897.
19. Carosi G, Rizzetto M. Treatment of chronic hepatitis B: recommendations from an Italian workshop. Dig Liver Dis 2008; 40:603-617.
20. Günther S, Li BC, Miska S, Krüger DH, Meisel H, Will H. A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J Virol 1995; 69:5437-5444.
21. Günther S, Sommer G, Von Breunig F, et al. Amplification of full-length hepatitis B virus genomes from samples from patients with low levels of viremia: frequency and functional consequences of PCR-introduced mutations. J Clin Microbiol 1998; 36:531-538.
22. Bartholomeusz A, Locarnini SA. Antiviral drug resistance: clinical consequences and molecular aspects. Semin Liver Dis 2006; 26:162-170.
23. Tillmann HL. Antiviral therapy and resistance with hepatitis B virus infection. World J Gastroenterol 2007; 13:125-140.
24. Lee Y-S, Suh DH, Lim Y-S, et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006; 43:1385-1391.
25. Gallego A, Sheldon J, Garcia-Samaniegio J, et al. Evaluation of initial virological response to ADV and development of adefovir-resistant mutations in patients with chronic hepatitis B. J Viral Hep 2008; 15:392-398.
26. Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associate with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125:292-297.
27. Villeneuve J-P, Durantel D, Durantel S, et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 2003; 39:1085-1089.
28. Lacombe K, Ollivet A, Gozlan J, et al. A novel hepatitis B virus mutation with resistance to adefovir but not to tenofovir in an HIV-hepatitis B virus co-infected patient. AIDS 2006; 20:2229-2236.
29. Moriconi F, Colombatto P, Coco P. et al. Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment. J Antimicrob Chemother 2007; 60:341-349.
30. Laoi BN, Herra C, Norris S, Crowley B. Hepatitis B virus resistance to adefovir in a nucleotide naive patient with chronic hepatitis B virus infection. J Antimicrob Chemother 2007; 59:807-809.
31. Villet S, Pichoud C, Villeneuve JP, Trepo C, Zoulim, F. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology 2006; 131:1253-1261.
32. Pollicino T, Maimone S, Isgro G, et al. Variability of the HBV pol gene reverse-transcriptase domain in viral isolates from untreated and lamivudine-resistant chronic hepatitis B patients. Dig Liver Dis 2007; 39:A7.
33. Bartholomeusz A, Kniper M, Angus P, et al. Molecular analysis of HBV polymerase mutations associated with dual adefovir and lamivudine resistance. J Hepatol 2006; 44 Suppl 2:S179.
34. Locarnini S, Qi X, Arterburn S, et al. Incidence and predictors of emergence of adefovir resistance HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB). J Hepatol 2005; 42 Suppl 2:17